Glycomics Firm Sialix Developing Auto Antibody-Based Tests for Breast, Colon, Prostate Cancers

The company, which has licensed intellectual property related to use of the auto-antibodies from UCSD, aims to develop the diagnostics first as CLIA-based tests and ultimately in a microarray format available to physicians.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.